High cholesterol is often dubbed the “silent killer” because it progresses for years without clear symptoms, until serious ...

Arcus senilis is caused due to the lipid build-ups in the cornea's blood vessels around the iris, which is a clear indication of declining cardiovascular health. Retinal vein occlusion (Blocked ...

HAYWARD, Calif., June 24, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to ...

Chennai: A new type of contact lens that can be worn overnight to help reshape the cornea and slow the eye's elongation, allowing people with myopia, .

Measurements of the curvature of the cornea of the eye can be significantly affected by the status of dry eye in a patient, according to a study published in Frontiers in Medicine. 1 Different ...

A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. View (RCUS) real-time stock price, chart, news, analysis, analyst reviews and more.

Corneal disease in patients with VKC and AKC ranges from Tranta's dots, superficial punctuate keratitis, shield ulcer, ... Pseudogerontoxon, which resembles arcus senilis, ...

Under the terms of the deal, Arcus received $375 million upfront, with another $1.225 billion in opt-in and milestone payments tied to clinical-stage candidates, which also include AB680, a small ...

Gilead and Arcus entered into a $2 billion alliance in 2021 in which Gilead exercised options on four drug candidates, including domvanalimab, follow-up TIGIT AB308, adenosine A2a/A2b receptor ...

Pseudogerontoxon, which resembles arcus senilis, is a waxing and waning grey-white lipid deposition in the superficial stroma of the peripheral cornea. It is an uncommon complication of VKC, and, ...